Suneva Medical has appointed Deepak Chadha to Vice President, Regulatory Affairs. With nearly two decades of regulatory experience, Chadha will be responsible for leading the development and implementation of Suneva Medical's regulatory strategies. Chadha comes to Suneva Medical after holding regulatory affairs positions at companies that include KYTHERA Biopharmaceuticals and Allergan Medical.
"Deepak has been responsible for several global regulatory strategies that have led to the successful submission and approval of aesthetic and therapeutic products in the U.S. and overseas," said Nicholas L. Teti, Jr., Chairman and CEO of Suneva Medical. "This track record is highly regarded by Suneva Medical, and we welcome Deepak to the team, as he will help us meet our vision to become a standout in the aesthetics market."
Prior to joining Suneva, Chadha held the role of Vice President, Regulatory Affairs at KYTHERA. During his time at KYTHERA, Chadha successfully led their lead compound ATX-101 from an early clinical phase to an NDA stage, and also supported the ex-US regulatory activities. He has also served as Vice President of Global Regulatory Affairs at Allergan Medical, helping build the organization's Global Regulatory Affairs department.
"I am pleased to join Suneva Medical's experienced management team and am optimistic that my role will help drive the company's growth strategy," said Chadha.
